DURECT Q1 2024 Earnings Preview
DURECT (NASDAQ:DRRX) is scheduled to announce Q1 earnings results on Monday, May 13th, after market close. The consensus EPS Estimate is -$0.22 (+57.7% Y/Y) and the consensus Revenue Estimate is ...
Nature21d
Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis
Subcutaneously implanted osmotic pumps (100 μl; Alzet corporation, Palo Alto, California) (for 24- and 48-hour time points) and 1-cm Silastic capsules (Dow-Corning corporation, Midland ...
BMJ23d
OP2 Knock-out of MG23 cardioprotects against pressure-overload induced cardiac hypertrophy and cardiac dysfunction
Pressure-overload was induced in MG23-knock out (KO) and wild type (WT) mice using Angiotensin II (AngII, 1.1 mg/kg/day) delivered subcutaneously by an osmotic mini pump (Alzet). Dynamic cardiac ...
Seeking Alpha7d
CRL Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and ...
ahajournals.org11d
Dll4 Suppresses Transcytosis for Arterial Blood-Retinal Barrier Homeostasis
From the Graduate School of Medical Science and Engineering (J.M.Y., C.S.P., S.H.K., T.W.N., J.-H.K., S.P., P.K., Y.S.J., I.K.), Korea Advanced Institute of Science ...
ahajournals.org7d
Iron Overload Augments Angiotensin II–Induced Cardiac Fibrosis and Promotes Neointima Formation
From the Department of Cardiovascular Medicine (N.I., K.S., H.M., M.S., S.U., M.O., R.N.), University of Tokyo Graduate School of Medicine; the Department of ...